Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What Comes First? FDA Excessive Claims Finding Or Facility Inspection?

This article was originally published in The Tan Sheet

Executive Summary

Recent warning letters to Reviva Labs and Ageless Derma manufacturer Crescent Health Center cite claims violations brought to FDA's attention through inspections of the companies' facilities. It's possible, however, that conspicuous website claims that overstep cosmetic boundaries are prompting inspections.


Related Content

Soap Maker Warned As FDA's Cosmetics Enforcement Activity Picks Up
FDA Warns Reviva Labs For Collagen-Building, Anti-Inflammatory Claims
FDA Warning Cites Ageless Derma's Anti-Wrinkle, Brightening Claims
FDA Cites Adulteration In Warning Letter To Juice Beauty Manufacturer
FDA Warning To L’Oreal Creates Uncertainty For Anti-Redness, Dark Spot Treatments
Rash Of FDA Warning Letters Raises Questions For Cosmetics Industry





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts